Washington: Pfizer and Biontech said on Monday the Covid-19 vaccine they remained 100 percent effective in children aged 12 to 15 years, four months after the second dose.
The company said that new data, involving 2,228 trial participants would help support their application for full approval in the United States and throughout the world.
There are no serious security problems observed in individuals with at least six months after follow-up after the second dose.
“When the global health community works to increase the number of people who are vaccinated throughout the world, this additional data provides further confidence in our vaccine safety and effectiveness profiles in adolescents,” said CEO of Pfizer Albert Bourla in a statement.
“This is very important because we see the climbing rate of Covid-19 in this age group in several regions, while vaccine absorption has slowed.
We hope to share this data with the FDA and other regulators.” This vaccine is given an “emergency use authorization” for adolescents by the US in May and the company plans to immediately seek full approval.
This vaccine is currently only fully approved in people aged 16 years and over.
Among 2,228 participants, there were 30 cases of simtomatic covid confirmed without evidence of previous infections, all in the placebo group.
This is in accordance with the efficacy of a 100 percent vaccine.
Performance is consistently high in all sex, race, obesity level and comorbidity status.
The concern of the main safety among this age group is the myocarditis regarding the vaccine (heart inflammation) in men.
But such cases are very rare, and the benefits of vaccination continue to exceed the risk, data has shown.
Covid itself can cause myocarditis, either more often and a more severe form.